Clinical Trial

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
Protocol Amendment History 3 changes
notable Enrollment increased: 20 -> 30 participants 2026-06-24
notable Primary completion moved earlier: 2029-05-24 -> 2027-04-22 2026-06-24
minor Completion moved earlier: 2029-05-24 -> 2028-05-17 2026-06-24
Trial Details
NCT Number NCT07203001
Lead Sponsor Novartis Pharmaceuticals
Conditions Still´s Disease
Enrollment 30 participants
Start Date 2025-11-03
Primary Completion 2027-04-22 (estimated)
Study Completion 2028-05-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-10